In addition to promoting a healthy lifestyle, integrating the latest evidence-based pharmacological therapies such as SGLT-2 inhibitors and GLP-1 receptor agonist into clinical practice may improve outcomes and enhance the overall management of PCOS-related CVD. Here, GLP1R is linked to polycystic ovary syndrome.